Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and valvular heart disease: The Loire Valley Atrial Fibrillation Project

European Heart Journal

Volumn 36, Issue 28, 2015, Pages 1822-1830

  Philippart, Raphael ^a   Brunet Bernard, Anne ^a   Clementy, Nicolas ^a   Bourguignon, Thierry ^a   Mirza, Alain ^a   Babuty, Dominique ^a   Angoulvant, Denis ^a   Lip, Gregory Y H ^b   Fauchier, Laurent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; CHA2DS2 VASc score; Stroke; Valve disease

Indexed keywords

AGED; ARTICLE; ATRIAL FIBRILLATION; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SCORING SYSTEM; THROMBOEMBOLISM; VALVULAR HEART DISEASE; COMPLICATION; KAPLAN MEIER METHOD; MORTALITY; PROCEDURES; SEVERITY OF ILLNESS INDEX; STROKE;

AGED; ATRIAL FIBRILLATION; FEMALE; HEART VALVE DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOEMBOLISM;

EID: 84938393511     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv163     Document Type: Article

References (22)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-988.
2. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-e575S.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-272.
4. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost 2012;107:1172-1179.
5. Taillandier S, Olesen JB, Clémenty N, Lagrenade I, Babuty D, Lip GY, Fauchier L. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study. J Cardiovasc Electrophysiol 2012;23:708-713.
6. Lip GY. Stroke andbleedingrisk assessment in atrialfibrillation: when, how, andwhy? Eur Heart J 2013;34:1041-1049.
7. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology. Eur Heart J 2010;31:2369-2429.
8. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. ESC Committee for Practice Guidelines-CPG; 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413.
9. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl.):e576S-e600S.
10. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-2496.
11. Poungvarin N, Opartkiattikul N, Chaithiraphan S, Viriyavejakul A. A comparative study of coumadin and aspirin for primary cardioembolic stroke and thromboembolic preventions of chronic rheumatic mitral stenosis with atrial fibrillation. J Med Assoc Thai 1994;77:1-6.
12. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt G, Le Heuzey JY, Prins MH, Lévy S, Crijns HJ; European Heart Survey Investigators. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-2434.
13. Cai H, Li Z, Goette A, Mera F, Honeycutt C, Feterik K, Wilcox JN, Dudley SC Jr, Harrison DG, Langberg JJ. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002;106:2854-2858.
14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100.
15. Avierinos JF, Brown RD, Foley DA, Nkomo V, Petty GW, Scott C, Enriquez-Sarano M. Cerebral ischemic events after diagnosis of mitral valve prolapse: a community-based study of incidence and predictive factors. Stroke 2003;34:1339-1344.
16. Nair CK, Aronow WS, Shen X, Anand K, Holmberg MJ, Esterbrooks DJ. Effect of mitral regurgitation on cerebrovascular accidents in patients with atrial fibrillation and left atrial thrombus. Clin Cardiol 2009;32:E7-E10.
17. Miyasaka Y, Tsuji H, Tokunaga S, Nishiue T, Yamada K, Watanabe J, Iwasaka T. Mild mitral regurgitation was associated with increased prevalence of thromboembolic eventsinpatients with nonrheumaticatrial fibrillation. Int J Cardiol 2000;72:229-233.
18. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T, Shimada K. Mitral regurgitation reducesthe riskof strokein patients with nonrheumaticatrial fibrillation. Am Heart J 1998;136:528-532.
19. FukudaN, HiraiT, OharaK, NakagawaK, NozawaT, InoueH. Relation oftheseverity of mitral regurgitation to thromboembolic risk in patients with atrial fibrillation. Int J Cardiol 2011;146:197-201.
20. Rodés-Cabau J, Dauerman HL, Cohen MG, Mehran R, Small EM, Smyth SS, Costa MA, Mega JL, O'Donoghue ML, Ohman EM, Becker RC. Antithrombotic Treatment in Transcatheter Aortic Valve Implantation: Insights for Cerebrovascular and Bleeding Events. J Am Coll Cardiol 2013;62:2349-2359.
21. Amat-Santos IJ, Rodés-Cabau J, Urena M, DeLarochellière R, Doyle D, Bagur R, Villeneuve J, Côté M, Nombela-Franco L, Philippon F, Pibarot P, Dumont E. Incidence, predictivefactors, and prognostic value of new-onsetatrial fibrillationfollowing transcatheter aortic valve implantation. J Am Coll Cardiol 2012;59:178-188.
22. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-749.